Disclaimer: Note that the firm is no longer accepting cases for the anti-psychotic medication Abilify or Tylenol autism cases. Thank you.
Select Page

The Michael Brady Lynch Firm Spearheads New Pradaxa Bleeding Lawsuits

This is Michael Brady Lynch, lead trial attorney for The Michael Brady Lynch Firm.
There is a sad misconception that those victims of uncontrollable Pradaxa bleeding who did not participate in the 2014 global settlement, or those who suffered uncontrollable bleeds after the settlement was announced, are somehow unable to pursue claims for their injuries. Nothing can be further from the truth.

The Michael Brady Lynch Firm refuses to stand by and watch big pharmaceutical companies collect dividends on your pain and suffering. We are leading the fight for those injured by uncontrollable bleeding and other damages caused by Pradaxa and its manufacturer, Boehringer Ingelheim Pharmaceuticals.


New Pradaxa Cases

We have filed two new cases against Boehringer Ingelheim in state court in California and Connecticut: Charles Adkins vs Boehringer Ingelheim Pharmaceuticals, Inc. and David Simpson’s Estate vs Boehringer Ingelheim Pharmaceuticals, Inc. Our office is also investigating hundreds of more cases of uncontrollable bleeding caused by Pradaxa usage.

In 2010, Boehringer Ingelheim spent $67 million promoting this dangerous medication even though Pradaxa was not approved for sale until Oct. 19th of that year. The company overstated the efficacy of Pradaxa with respect to preventing stroke and systemic embolism and failed to meaningfully disclose there is no drug to reverse the anticoagulation effects of Pradaxa. In addition, they failed to warn emergency room doctors, surgeons and other critical care specialists that there is no effective agent to stabilize patients who experience uncontrollable bleeding while taking Pradaxa. If Boehringer Ingelheim had acted with patient safety as a priority instead of profits, they may have prevented the uncontrollable bleeding of our clients Mr. Adkins and Mr. Knowles.

Plaintiff, Charles Adkins, found himself prescribed Pradaxa after bypass surgery and pacemaker placement. It was supposed to help his Atrial Fibrillation (AFib). Unfortunately for Mr. Adkins and many other people, Pradaxa made his health worse. After a month of black, tarry stools and escalating chest pain, Mr. Adkins was rushed to the hospital where he was placed in the ICU. His doctor diagnosed him with massive Gastrointestinal bleeding (GI bleed).


First New Case

However, they couldn’t figure out what was causing the dangerous GI bleed. Mr. Adkins needed life-saving measures to stop the bleeding ASAP, causing him to undergo painful bowel resection surgery. Due to the massive amount of blood he lost from the bleed, Mr. Adkins needed 12 units of packed red blood cells. Upon admittance to the ICU, his blood count was only 5.9; the normal level for an adult male is around 15.

Since Mr. Adkins needed a transfusion, his doctor stopped all his medications, including Pradaxa. It was during this time of the drug that doctors realized all his issues were stemming from his Pradaxa use. If his doctors didn’t make this connection, Charles Adkins may not be alive today. He would have continued to experience life-threatening GI bleeds, which may have eventually killed him.



Second New Case

Similarly, The Michael Brady Lynch Firm represents another unfortunate victim in the plaintiff, David Simpson. Mr. Simpson and his doctors took the claims of Boehringer Ingelheim about the safety and effectiveness of Pradaxa to be true when they prescribed Pradaxa for the treatment of Mr. Simpson’s AFib. Shortly thereafter, Mr. Simpson suffered severe gastrointestinal bleeding. Pradaxa caused and worsened his condition. Pradaxa was a substantial contributing factor to Mr. Simpson’s death on November 19, 2014.



Holding Boehringer Ingelheim Responsible

It is stories like these that push us to keep fighting for compensation for those injured by Pradaxa. In only two years since Pradaxa went to market, it may have caused more than 500 deaths. Yet, Boehringer Ingelheim still refuses to acknowledge that Pradaxa is defective and unreasonably dangerous in that the labeling is insufficient to adequately warn physicians and users of the increased risk of excessive and/or uncontrollable bleeding. Boehringer Ingelheim settled more than 4,000 of these claims in 2014 alone – paying $650 million. Sadly, many consumers who suffered Pradaxa bleeds were unaware of the settlement and many others suffered bleeds after the settlement was finalized.

Also, you have our word that The Michael Brady Lynch Firm will continue to be the watchdogs against pharmaceutical injustice. We will continue pioneering suits like the one filed for Charles Adkins and David Simpson against the manufacturers of Pradaxa to seek just compensation and ensure no one else suffers these life-threatening complications.

If you or a loved one experienced uncontrollable bleeding from using Pradaxa, please call us at 877-513-9517. Let’s fight this together.

What Our Clients Are Saying